{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:55:08Z","timestamp":1793994908549,"version":"4.8.0"},"reference-count":48,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"New Taipei Municipal TuCheng Hospital (built and operated by Chang Gung Medical Foundation), New Taipei City, Taiwan","award":["CORPVVL0041"],"award-info":[{"award-number":["CORPVVL0041"]}]},{"name":"New Taipei Municipal TuCheng Hospital (built and operated by Chang Gung Medical Foundation), New Taipei City, Taiwan","award":["NSTC 112-2314-B-182A-111-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-182A-111-MY3"]}]},{"name":"National Science and Technology Council of Taiwan, Republic of China","award":["CORPVVL0041"],"award-info":[{"award-number":["CORPVVL0041"]}]},{"name":"National Science and Technology Council of Taiwan, Republic of China","award":["NSTC 112-2314-B-182A-111-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-182A-111-MY3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies and has a poor prognosis. Ataxia telangiectasia mutated and Rad3 related (ATR) is a key regulator for the DNA damage response and a potential target to treat cancer. Methods: We assessed the efficacy of BAY 1895344, an ATR inhibitor, in three ATC cell lines. Results: BAY 1895344 caused dose\u2013response cytotoxicity in three ATC cell lines. BAY 1895344 induced S-phase and G2-phase arrest, activated caspase-3 activity and induced apoptosis in ATC cells. BAY 1895344 meaningfully retarded the tumor growth of an ATC xenograft model. BAY 1895344 therapy, combined with dabrafenib and trametinib, had synergism in vitro and revealed robust tumor growth suppression in vivo in two xenograft models of ATC harboring mutant BRAFV600E. Furthermore, the combination of BAY 1895344 with lenvatinib was more effective than either agent alone in a xenograft model of ATC. Conclusions: These results reveal that BAY 1895344 has potential in treating ATC.<\/jats:p>","DOI":"10.3390\/cancers17030359","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:09:02Z","timestamp":1737544142000},"page":"359","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting Ataxia Telangiectasia-Mutated and Rad3-Related for Anaplastic Thyroid Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-9685","authenticated-orcid":false,"given":"Shu-Fu","family":"Lin","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City 23652, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuen","family":"Hsueh","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan"},{"name":"Department of Pathology, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Chao","family":"Chou","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Pharmacology Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.canep.2018.01.011","article-title":"Anaplastic thyroid carcinoma in Denmark 1996\u20132012: A national prospective study of 219 patients","volume":"53","author":"Hvilsom","year":"2018","journal-title":"Cancer Epidemiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1530\/EJE-16-0574","article-title":"Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: Results of a multicenter study in Germany","volume":"175","author":"Wendler","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00268-012-1437-z","article-title":"Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC research consortium of Japan cohort study of 677 patients","volume":"36","author":"Sugitani","year":"2012","journal-title":"World J. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting anaplastic thyroid carcinoma: A comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 Cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/thy.2016.0395","article-title":"Patterns of treatment failure in anaplastic thyroid carcinoma","volume":"27","author":"Rao","year":"2017","journal-title":"Thyroid"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Al-Jundi, M., Thakur, S., Gubbi, S., and Klubo-Gwiezdzinska, J. (2020). Novel targeted therapies for metastatic thyroid cancer-a comprehensive review. Cancers, 12.","DOI":"10.3390\/cancers12082104"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Choi, S., Shugard, E., Khanafshar, E., Quivey, J.M., Garsa, A.A., and Yom, S.S. (2016). Association between BRAF V600E mutation and decreased survival in patients locoregionally irradiated for anaplastic thyroid carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 96.","DOI":"10.1016\/j.ijrobp.2016.06.1526"},{"key":"ref_8","first-page":"5342","article-title":"The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: A multi-institutional retrospective study in Taiwan","volume":"12","author":"Chang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: Updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cance","volume":"16","author":"Tang","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1101\/gad.214080.113","article-title":"ATR phosphorylates SMARCAL1 to prevent replication fork collapse","volume":"27","author":"Couch","year":"2013","journal-title":"Genes Dev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Molinuevo, R., Freije, A., Contreras, L., Sanz, J.R., and Gandarillas, A. (2020). The DNA damage response links human squamous proliferation with differentiation. J. Cell Biol., 219.","DOI":"10.1083\/jcb.202001063"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","article-title":"Synthetic lethal therapies for cancer: What\u2019s next after PARP inhibitors?","volume":"15","author":"Ashworth","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: Beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2018.03.005","article-title":"Targeting the replication stress response in cancer","volume":"188","author":"Forment","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev-genet-121415-121658","article-title":"Functions, regulation, and therapeutic implications of the ATR checkpoint pathway","volume":"50","author":"Yazinski","year":"2016","journal-title":"Annu. Rev. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.yexcr.2014.09.019","article-title":"Replication stress and cancer: It takes two to tango","volume":"329","author":"Lecona","year":"2014","journal-title":"Exp. Cell Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: An essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10334","DOI":"10.1093\/nar\/gkt833","article-title":"ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage","volume":"41","author":"Gamper","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.molcel.2015.12.016","article-title":"TPP1 blocks an ATR-mediated resection mechanism at telomeres","volume":"61","author":"Kibe","year":"2016","journal-title":"Mol. Cell."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.molcel.2016.12.007","article-title":"Coupling of homologous recombination and the checkpoint by ATR","volume":"65","author":"Buisson","year":"2017","journal-title":"Mol. Cell."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","article-title":"Hollingsworth, Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: A phase I study","volume":"27","author":"Yap","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13045-019-0733-6","article-title":"Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: Where we stand","volume":"12","author":"Mei","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"AACR Project GENIE Consortium (2017). AACR Project GENIE: Powering precision medicine through an international consortium. Cancer Discov., 7, 818\u2013831.","DOI":"10.1158\/2159-8290.CD-17-0151"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancermodels","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1210\/jc.2008-1102","article-title":"Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification","volume":"93","author":"Schweppe","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_34","first-page":"583","article-title":"Establishment of 2 human thyroid-carcinoma cell-lines (8305c, 8505c) bearing p53 gene-mutations","volume":"4","author":"Ito","year":"1994","journal-title":"Int. J. Oncol."},{"key":"ref_35","first-page":"1857","article-title":"Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines","volume":"82","author":"Ain","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Lin, S.F., Huang, Y.Y., Lin, J.D., Chou, T.C., Hsueh, C., and Wong, R.J. (2012). Utility of a PI3K\/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046726"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.surg.2007.09.017","article-title":"Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus","volume":"142","author":"Lin","year":"2007","journal-title":"Surgery"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_39","unstructured":"Chou, T.C., and Martin, N. (2024, December 14). CompuSyn for Drug Combinations: PC software and Users Guide: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations and the Determination of IC50, ED50, and LD50 Values. Available online: www.combosyn.com."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/ERC-21-0001","article-title":"Efficacy of adavosertib therapy against anaplastic thyroid cancer","volume":"28","author":"Lu","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"7","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1038\/s41467-022-32023-7","article-title":"Therapeutic targeting of ATR in alveolar rhabdomyosarcoma","volume":"13","author":"Pusch","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of Lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1089\/thy.2013.0610","article-title":"Concomitant RAS, RET\/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma","volume":"24","author":"Zou","year":"2014","journal-title":"Thyroid"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","article-title":"AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity","volume":"10","author":"Fok","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Trenner, A., and Sartori, A.A. (2019). Harnessing DNA double-strand break repair for cancer treatment. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01388"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e230142","DOI":"10.1530\/ERC-23-0142","article-title":"Therapeutic inhibition of ATR in differentiated thyroid cancer","volume":"30","author":"Lin","year":"2023","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/359\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:33:58Z","timestamp":1759919638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17030359"],"URL":"https:\/\/doi.org\/10.3390\/cancers17030359","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]}}}